StrideBio Closes $81.5M Series B Financing

17 Mar, 2021

StrideBio Closes $81.5M Series B Financing
Photo by Mathieu Stern on Unsplash

– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.

Biotechnology Health Care Information Technology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: